COMUNICACIONES A CONGRESOS
AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).
Marme F, Pautier P, Van Nieuwenhuysen E, Reuss A, Redondo A, Lindemann K, Kurzeder C, Marth C, Burges A, Pietzner K, Wimberger P, De Gregorio N, Harter P.
Citation: J Clin Oncol 37, 2019 (suppl; abstr TPS5601).
BEATcc (ENGOT-Cx10/GEICO 68-C/GOG3030/JGOG1084): A randomized, open label, phase III study of cisplatin and paclitaxel chemotherapy with bevacizumab (CTx plus B) with or without atezolizumab (Atz) as first-line treatment for metastatic, persistent, or recurrent (m/r) carcinoma of the cervix (CCx).
Oaknin A, Gladieff L, Colombo N, Villacampa G, Mirza MR, De Giorgi U, Randall LM, Takekuma M, González-Martín A.
Citation: J Clin Oncol 37, 2019 (suppl; abstr TPS5594)
ENGOTOv41/GEICO-69-O/ANITA trial: A phase III randomized, double-blinded trial of platinum-based chemotherapy (CT) with or without atezolizumab (ATZ) followed by niraparib maintenance with or without ATZ in patients with recurrent ovarian, tubal or peritoneal cancer (OC) and platinum treatment-free interval (TFIp) >6 months.
González-Martín A, Colombo N, Heitz F, dePont Christensen R, Selle F, Vergote I, Oaknin A.
Citation: J Clin Oncol 37, 2019 (suppl; abstr TPS5599).
DUO-O: A randomized Phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.
Harter P, Bidziński M, Colombo N, Floquet A, Rubio Pérez MJ, Kim JW, Lheureux S, Marth C, Nyvang G-B, Okamoto A, Reuss A, Scambia G, Trillsch F, Vardar MA, Van Nieuwenhuysen E, Lichfield J, Rugman P, Twumasi-Ankrah P, Aghajanian C.
Citation: J Clin Oncol 37, 2019 (suppl; abstr TPS5598).
ENGOTOV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCAnonmutated advanced epithelial ovarian cancer.
Vergote I, Sehouli J, Salutari V, Zola P, Madry R, Wenham RM, Korach J, Pautier P, Cibula D, Lheureux S, Hasegawa K, Kim BG, Lai CH, González-Martín A, Liu Q, Keefe SM, Puglisi M, Topuz S.
Citation: J Clin Oncol 37, 2019 (suppl; abstr TPS5603).
ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC).
Hardy-Bessard AC, Moore KN, Mirza MR, Asselain B, Redondo A, Pfisterer J, Pignata S, Provencher DM, Cibula D, Reyners AKL, Bodnar L, Glasspool RM, Papadimitriou CA, Eitan R, Han S, Duska LR, Rimel BJ, Hazard S, Chen J, Pujade-Lauraine E.
Citation: J Clin Oncol 37, 2019 (suppl; abstr TPS5600).
CD8+ TILs in early stage epithelial ovarian cancer: A GEICO study.
Ignacio Romero, Susanna Leskella, Andres Redondo, Ana Gutierrez-Pecharroman, Ana Santaballa, Eva Maria Cristobal Lana, Elisa Calvo, Juan Manuel Rosa-Rosa, Ana Oaknin, Isabel Bover, Ana Herrero, Ana Beatriz Sanchez-Heras, Cristina Maria Churruca, Ana De Juan, Cesar Mendiola, Margarita Romeo, Belen Ojeda, Jose Antonio Lopez-Guerrero, José Palacios, Andres Poveda, GEICO Group.
2017 ASCO Annual Meeting. Session Type:Poster Session. Session Title:Gynecologic Cancer. Subtrack:Ovarian Cancer.Abstract #:5543. Citation: J Clin Oncol 35, 2017 (suppl; abstr 5543).
Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC) (GEICO 1205/NOVA TRIAL).
Yolanda Garcia Garcia, Ana De Juan, Cesar Mendiola, Maria Pilar Barretina-Ginesta, Aleix Prat, Ana Santaballa, Isabel Bover, Marta Gil-Martin, Aránzazu Manzano, M Jesus Rubio, Margarita Romeo, Cristina Arqueros, Elena Garcia Martinez, Antonio Gonzalez Martin.
2017 ASCO Annual Meeting. Presented Friday, June 2, 2017. Session Type: Oral Abstract Session. Session Title: Gynecologic Cancer. Track: Gynecologic Cancer.Subtrack: Ovarian Cancer. Abstract #:5508. Clinical Trial Registry Number: 2012-003883-31. Citation: J Clin Oncol 35, 2017 (suppl; abstr 5508). 2017 Annual Meeting Proceedings Notices.
Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).
Ursula A. Matulonis, Jorn Herrstedt, Anna Tinker, Frederik Marme, Andres Redondo, Elsa Kalbacher, Jonathan A. Ledermann, Joanna Pikiel, Rene dePont Christensen, Jonathan S. Berek, Trine Juhler-Nøttrup, Amit M. Oza, Werner Meier, Marta Gil-Martin, Anne-Claire Hardy-Bessard, Bradley J. Monk, Per Rosenberg, Robert Michael Wenham, Sebastien Hazard, Mansoor Raza Mirza, For the ENGOT-OV16/NOVA Investigators.
2017 ASCO Annual Meeting. Category: Gynecologic Cancer. Sub-category: Ovarian Cancer. Abstract No: 5534. Poster Board Number: Poster Session (Board #356). Citation: J Clin Oncol 35, 2017 (suppl; abstr 5534).
Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy.
Mansoor Raza Mirza, Bradley J. Monk, Marta Gil-Martin, Lucy Gilbert, Ulrich Canzler, Philippe Follana, Justin S. Waters, Frederic Kridelka, Tally Levy, Benedict B. Benigno, Kathrine Woie, Diane M. Provencher, Hans-Joachim Lueck, Antonio Casado Herraez, Anne Lesoin, Joseph Buscema, Kristina Hellman, Bj Rimel, Sebastien Hazard, Ursula A. Matulonis, For the ENGOT-OV16/NOVA Investigators.
Sub-category: Ovarian Cancer. Category: Gynecologic Cancer. Meeting: 2017 ASCO Annual Meeting. Abstract No: 5517.Poster Board Number: Poster Discussion Session (Board #339). Citation: J Clin Oncol 35, 2017 (suppl; abstr 5517).
The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC).
Jose Maria Del Campo, Mansoor Raza Mirza, Jonathan S. Berek, Diane M. Provencher, Guenter Emons, Michel Fabbro, Rosemary Lord, Nicoletta Colombo, Edgar Petru, Robert Michael Wenham, Jorn Herrstedt, Lucy Gilbert, Martin Leonhard Heubner, Antonio Gonzalez Martin, Philippe Follana, Benedict B. Benigno, Anne Dørum, Bj Rimel, Sebastien Hazard, Ursula A. Matulonis, For the ENGOT-OV16/NOVA Investigators.
Sub-category: Ovarian Cancer. Category:Gynecologic Cancer. Meeting: 2017 ASCO Annual Meeting. Abstract No: 5560. Poster Board Number: Poster Session (Board #382). Citation: J Clin Oncol 35, 2017 (suppl; abstr 5560).
Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.
Jonathan A. Ledermann, Andrew C. Embleton, Timothy Perren, Gordon C. Jayson, Gordon J. S. Rustin, Stanley B. Kaye, Hal W. Hirte, Amit M. Oza, Michelle Margaret Vaughan, Michael Friedlander, Antonio Gonzalez Martin, Elizabeth Clark, Babasola O Popoola, Laura Farrelly, Ann Marie Swart, Adrian Cook, Richard S. Kaplan, Mahesh K B Parmar, ICON6 Collaborators.
Sub-category: Ovarian Cancer. Category: Gynecologic Cancer. Meeting: 2017 ASCO Annual Meeting. Session: Gynecologic Cancer .Type: Oral Abstract Session. Abstract No: 5506. Citation: J Clin Oncol 35, 2017 (suppl; abstr 5506).
Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer.
David M. O’Malley, Kathleen N. Moore, Ignace Vergote, Lainie P. Martin, Lucy Gilbert, Antonio Gonzalez Martin, Dale L. Nepert, Rodrigo Ruiz-Soto, Michael J. Birrer, Ursula A. Matulonis.
Session: Gynecologic Cancer. Type: Poster Session. Sub-category: Ovarian Cancer. Category: Gynecologic Cancer. Meeting: 2017 ASCO Annual Meeting. Abstract No: 5553. Poster Board Number:Poster Session (Board #375). Citation: J Clin Oncol 35, 2017 (suppl; abstr 5553).
Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20.
Andreas Du Bois, Ignace Vergote, Gwenael Ferron, Alexander Reuss, Werner Meier, Stefano Greggi, Pernille Tina Jensen, Frédéric Selle, Frederic Guyon, Christophe Pomel, Fabrice Lecuru, Rongyu Zang, Elisabeth Avall-Lundqvist, Jae Weon Kim, Jordi Ponce, Francesco Raspagliesi, Sadaf Ghaem-Maghami, Alexander Reinthaller, Philipp Harter, Jalid Sehouli.
Sub-category: Ovarian Cancer. Category: Gynecologic Cancer. Session: Gynecologic Cancer. Type: Oral Abstract Session . Meeting: 2017 ASCO Annual Meeting. Abstract No: 5501. Citation: J Clin Oncol 35, 2017 (suppl; abstr 5501).
PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.
Isabelle Laure Ray-Coquard, Philipp Harter, Antonio Gonzalez Martin, Claire Cropet, Sandro Pignata, Keiichi Fujiwara, Christian Marth, Ignace Vergote, Mansoor Raza Mirza, Nicoletta Colombo, Per Rosenberg, Johanna Unelma Maenpaa, Eric Pujade Lauraine.
Session: Gynecologic Cancer. Type: Poster Session. Sub-category: Ovarian Cancer. Category: Gynecologic Cancer. Meeting: 2017 ASCO Annual Meeting. Abstract No:TPS5605. Poster Board Number: Poster Session (Board #424b). Citation: J Clin Oncol 35, 2017 (suppl; abstr TPS5605).
Postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer: The ENGOT-EN2/DGCG trial.
Mansoor Raza Mirza, Caroline Lundgren, Frederic Kridelka, Annamaria Ferrero, Stefano Greggi, Rene dePont Christensen, Ana Santaballa, Pamela T. Soliman, Tally Levy, Jalid Sehouli, David Cibula, Annika Auranen, Bente Lund, Eva Roennengart, Frederic Amant.
Sub-category:Uterine Cancer. Category: Gynecologic Cancer. Session: Gynecologic Cancer. Type: Poster Session. Meeting: 2017 ASCO Annual Meeting. Abstract No:TPS5613. Poster Board Number: Poster Session (Board #428b). Citation: J Clin Oncol 35, 2017 (suppl; abstr TPS5613).
Palbociclib versus placebo in combination with letrozole for patients with advanced or recurrent endometrial cancer: The NSGO ENGOT-EN3/PALEO trial.
Mansoor Raza Mirza, Vanda Salutari, Cesar Mendiola, Jalid Sehouli, Rene dePont Christensen, Line Bjorge, Sandro Pignata, Marta Gil-Martin, Radoslav Chekerov, Gitte-Betina Nyvang, Domenica Lorusso, Maria Pilar Barretina-Ginesta, Frederic Marme, Graziana Ronzino, M Jesus Rubio, Ingo B. Runnebaum, Trine Juhler-Nøttrup, Joan Løhndorf, Annika Auranen.
Sub-category:Uterine Cancer. Category: Gynecologic Cancer. Session: Gynecologic Cancer. Type: Poster Session. Meeting: 2017 ASCO Annual Meeting. Abstract No: TPS5612. Poster Board Number:Poster Session (Board #428a). Citation: J Clin Oncol 35, 2017 (suppl; abstr TPS5612).
LBA3_PR – A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer.
M.R. Mirza1, B.J. Monk2, A. Oza3, S. Mahner4, A. Redondo5, M. Fabbro6, J. Ledermann7, D. Lorusso8, I.B. Vergote9, O. Rosengarten10, J. Berek11, J. Herrstedt12, A.V. Tinker13, A. Dubois14, A. Gonzalez Martin15, P. Follana16, B. Benigno17, B.J. Rimel18, S. Agarwal19, U. Matulonis
08 October 2016 Event: ESMO 2016 Congress Session. Presidential Symposium 1. Topics: Ovarian Cancer. Presenter: Mansoor Raza Mirza. Citation: Annals of Oncology (2016) 27 (6): 1-36. 10.1093/annonc/ mdw435
Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study).
I. Romero, M.J. Rubio, R. Serrano, M. Medina, L. Minig, A. Casado, P. Coronado, S. Martínez, C. Orbegoso, P. Fusté, E.M. Guerra Alia, M.C. Sánchez-Martínez, D. Rubio, M. Santacana, M. Ruiz, A. Llombart-Cussac, X. Matias-Guiu, A.M. Poveda.
ESMO 2016. Poster session. Ann Oncol (2016) 27 (suppl_6): 903TiP. DOI:https://doi.org/10.1093/annonc/mdw374.50. Published: 11 October 2016.
Computed tomography is more sensitive than CA 125 in detecting disease progression in patients with platinum-resistant ovarian cancer: Analysis of the AURELIA trial
K. Lindeman, G. Kristensen, M. Raza Mirza, L. Davies, F. Hilpert, I. Romero, A. Ayhan, A. Burges, M.J. Rubio, F. Raspagliesi, M. Huizing, G.J. Creemers, M. Lykka, C. Lee, V. G
ESMO 2015 Comunicación Oral. EJC. Volume 51, Supplement S3, September 2015. ISSN 0959-8049. Abstract number: 2703. Oral Session: Gynaecological Cancer
ROSE study: A retrospective evaluation of clinical management of advanced ovarian cancer (AOC) in Spain by the Spanish Group for Research in Ovarian Cancer (GEICO)
R. Gironés, J.L. Alonso, A. Arcusa, A.B. Sánchez, P. Barretina, P. Borrega, J. Cueva, J.D. Alarcón, M.C. Esteban, J. Fuentes, A. García, L. Garrigos, E. Guerra, A. Herrero, N. Lainez, C. Maximiano, P. Martínez, A. González-Martín.
ESMO 2015 Poster session. EJC. Volume 51, Supplement S3, September 2015. ISSN 0959-8049. Abstract number: 2774. Poster Session: Gynaecological Cancer
Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC) (GEICO 1205/NOVA TRIAL).
Yolanda García, Ana De Juan, Cesar Mendiola, Pilar Barretina-Ginesta, Laura Vidal, Ana Santaballa, Isabel Bover, Marta Gil-Martin, Aránzazu Manzano, M Jesus Rubio, Margarita Romeo, Alfonso Gomez de Liaño, Elena García-Martínez, Antonio Gonzalez-Martin.
ASCO 2015 Poster session.
CLINICAL DIFFERENCES AMONG STAGE IC OVARIAN CARCINOMA: A GEICO PROSPECTIVE EARLY STAGE DATABASE ANALYSIS
I. Romero, J.A. Lopez-Guerrero, J.M. DEL CAMPO, C. Churruca, N. Lainez, A. Redondo, E. Calvo, A. Herrero, I. Bover, A. Santaballa, E. Garcia-Martinez, C. Caballero, B. Sanchez-Heras, B. Ojeda, M. Romeo, C. Mendiola, A. Casado, J. Martinez, R. Girones, A. Poveda
IGCS 2014 Poster session.
1630P – Genomic characterization of early stages of ovarian cancer with emphasis in low-grade endometroid and low-grade serous histologies. A study by Spanish Group for Ovarian Cancer Research (GEICO)
I. Romero (Valencia, Spain) J. Lopez Guerrero (Valencia, Spain) J. Palacios (Madrid, Spain) B. Ojeda (Barcelona, Spain) C. Illueca (Valencia, Spain) A. Gutierrez Pecharromán (Madrid, Spain) S. Blanch (Valencia, Spain) E. Cristóbal (Madrid, Spain) M. Garcia Casado (Valencia, Spain) B. Vieites (Sevilla, Spain) I. Ruiz Díaz (San Sebastián, Spain) F. Vera Sempere (Valencia, Spain) F. Pastor (Murcia, Spain) E. Andrada (Eleche, Spain) M. Culubret (Terrasa, Spain) D. Hardisson (Madrid, Spain) E. Calvo (Sevilla, Spain) C. Churruca (San Sebastián, Spain) A. Santaballa (Valencia, Spain) A. M. Poveda (Valencia, Spain)
ESMO 2014 Poster session.
Genomic alterations in paired pretreatment (pre) and progression (prog) tumor samples from ovarian cancer patients (pts) treated with pazopanib (pazo) or placebo (plb).
R. Alvarez Gallego, N. Lainez, A. Poveda
ASCO 2014 Oral Abstract Session.
PHASE II trial of intraperitoneal (IP) administration of catumaxomab (C) as consolidation therapy for patients (pts) with relapsed epithelial ovarian cancer (OC) in second or third complete remission: GEICO 1001 study
I Romero, A Oaknin, JA Arranz, H García-Martinez, A Herrero, A Casado, A De Juan, E Guerra, S Hernando, A Santaballa, A Poveda, A Gonzalez-Martin
ASCO 2014 Poster Highlight Session.
Pertuzumab (P) + chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial
A. González, JM del Campo
ASCO 2014 General Poster Session.
Central pathology review of early-stage ovarian carcinoma: Description and correlation with follow-up—A study by the Spanish Group for Ovarian Cancer Research (GEICO)
José Antonio López-Guerrero, Ana Gutierrez Pecharromán, José Palacios Calvo, Ignacio Romero, Eva Cristobal Lana, David Hardisson, Francisco Vera-Sempere, Carmen Illueca, Begoña Vieites, Ángel García, Javier Ibarra de la Rosa, Sofía Hakin Alonso, Rosa Guarch Troyas, Encarna Andrada, Santiago Montes, Francisco Pastor, Ma Carmen Gomez, Ma Amparo Torroba, Emanuela D’Angelo, Andrés Poveda
ASCO 2014 General Poster Session.
Abstract Title: Early-stage ovarian cancer: Clinical outcome and analysis of prognostic factors—Results from a prospective registry of GEICO (Spanish Group for Ovarian Cancer Research).
Belen Ojeda, Cristina Maria Churruca, Ignacio Romero, Andrés Redondo, Elisa Calvo, Ana Santaballa, Josep M. del Campo, Ana Sebio, Nuria Laínez, Isabel Bover, Margarita Romeo, Cristina Caballero, Elena García-Martínez, Jeronimo Martinez Sr., Ana Herrero, Ana Beatriz Sánchez, Ana De Juan, Susana Hernando Polo, Nuria Ruiz, Andres Poveda
ASCO 2014 General Poster Session.
A phase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or Fallopian tube cancer (FTC): A Spanish Ovarian Cancer Group (GEICO) study
A.Oaknin; A. Gonzalez-Martin, Y. Garcia, S. Catot; C. Caballero; J. García- Donas; I. Bover, A. Santaballa; E. Guerra; B. Pardo; L. Vidal; R. Marquez; V. Rodriguez- Frexinos; I .Romero; A.Poveda.
J Clin Oncol 30, 2012 (suppl; abstr 5068). General Poster Session: Gynecologic Cancer.
AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) + chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)
Eric Pujade-Lauraine, Felix Hilpert, Beatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias, Deolinda Pereira, Pauline Wimberger, Ana Oaknin, Mansoor Raza Mirza, Philippe Follana, David Bollag, Isabelle Ray-Coquard.
J Clin Oncol 30, 2012 (suppl; abstr LBA5002^). Oral Presentation: Gynecologic Cancer.
Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): Results from OCTAVIA
Antonio Gonzalez-Martin, Laurence Gladieff, Bengt Tholander, Daniel Stroyakovsky, Martin Eric Gore, J. G. M. Segalla, An K.L Reyners, Nadezhda Kovalenko, Ana Oaknin, Frédéric Selle, David T. Bollag, Sandro Pignata.
J Clin Oncol 30, 2012 (suppl; abstr 5017^). Poster Discussion Session: Gynecologic Cancer.
Bevacizumab alone or with chemotherapy in highly pretreated, relapsed, epithelial ovarian cancer patients
B. Ojeda, A. Casado, A. Tibau, A. Redondo, M. Beltran, E. Garcia-Martinez, A. Santaballa, B. Pardo, P. Lianes, I. Bover, J. Garcia-Donas, C. M. Churruca, J. F. Cueva, A. B. Sanchez-Heras, M. M. Gordon-Santiago, A. Arcusa Lanza, A. Lopez-Rodriguez, C. Caballero, M. E. Ortega-Izquierdo, A. González-Martín.
ASCO Congress 2011, abstract e15590
Expression of DNA repair genes as biomarkers of outcome in Epithelial Ovarian Cancer: a GEICO study
A. Poveda, A. Casado, A. Cervantes, M. Tarón, I. Romero, I. Bover, A. González Martín, A. Oaknin, B. Ojeda, J.A. Lopez Guerrero.
ESMO Congress 2010, abstract 979PD
Feasibility of a modified outpatient regimen of intravenous/ intraperitoneal chemotherapy (IV/IP) in optimally debulked stage III ovarian cancer patients: A GEICO Study
A. Oaknin; D. Roda; A. Gonzalez-Martin; J. Garcia-Donas; A. De Juan; A. Redondo; S. Catot; J.M. Del Campo; X. Perez; A. Poveda.
ESMO Congreso 2009
Phase II study of weekly topotecan in recurrent of metastatic cervical cancer: a GEICO Study
M.J. Rubio, A. Santaballa, Y. García, A. González, I. Bover, E. Calvo, J.A. Contreras, J.M. Del Campo, A. de Juan, A. Poveda.
J Clin Oncol; 26. ASCO congress 2008 (abst. 5591)
Feasibility and Toxicity of modified outpatients regimen of intraperitoneal chemotherapy (IP) in optimally debulked stage III ovarian cancer patients
A. Oaknin, A. Cervantes, J. García, Y. García. A. de Juan, S. Catot, X. Pérez, J.M. Campo, A. González, A. Poveda.
12th Biennal Meeting International Gynecologic Society-IGCS. 2008:406
Early CA-125 response pattern in patients with recurrent ovarian cancer treated with pegilated liposomal doxorrubicin (PLD)
A. Oaknin, P. Barretina, L. Jiménez, X. Pérez, M. Velasco, M. Alsina, B. Pardo, J. Brunet, J.R. Germá, M. Beltran.
Ann Oncol; 19 (suppl 8). ESMO congress 2008: 680P.
Early stages (I-IIA) epithelial ovarian cancer (EOC): Preliminary data of the prospective register of the Spanish Group on Research of Ovarian Cancer (GEICO)
N. Ruíz, JM del Campo, E. Calvo, A. Santaballa, C. Churruca, A. Herrero, A. Casado, N. Lainez, A. Poveda, B. Ojeda.
ESMO congress 2008
“Topotecan in platinum resistant advanced ovarian cancer patients”. Evaluation of activity and prognostic factors of response: preliminary results
A study of Spanish Group for Research on Ovarian Cancer (GEICO). V.Soriano, C.Balañá, M.A.Izquierdo, A.Herrero, J.M. del Campo, A.Cervantes, A.Poveda, I.Bover, A.Casado, A.Arcusa, B.Ojeda, T.Massuti, I.Tusquets, I.Álvarez, E.Calvo.
Ann Oncol 2000 (suppl 4):85
A combination of a fixed dose of Carboplatin plus Paclitaxel and Adriamycin in first-line therapy for advanced ovarian cancer and subopimal surgical cytorreduction A phase I trial of the Spanish Group for Ovarian Cancer Research and treatment (GEICO)
A.Cervantes, A.Poveda, A.González, B.Massuti, C.Balañá, A.Insa.
Eur J Cancer 1999; 35(suppl 4): S239
A phase II trial of high dose single agent paclitaxel as first line therapy in advanced ovarian cancer
A. Cervantes, A. Escobedo, JM del Campo, A. Poveda, MD Benito, JR Germá-Lluch.
Ann Oncol 1996; 7 (suppl 5): 76.
